This monograph examines the contribution of imaging modalities to the stages of drug discovery and development, from early target validation to their use in clinical development programs. Chapters are devoted to the description of the drug discovery process, to the various imaging modalities preclinically and clinically, to applications of imaging during the optimization of a lead compound, addressing issues such as bioavailability and efficacy, and during drug safety evaluation.
This monograph examines the contribution of imaging modalities to the stages of drug discovery and development, from early target validation to their use in clinical development programs. Chapters are devoted to the description of the drug discovery process, to the various imaging modalities preclinically and clinically, to applications of imaging during the optimization of a lead compound, addressing issues such as bioavailability and efficacy, and during drug safety evaluation.
The drug discovery process.- Imaging modalities: principles and information content.- Magnetic resonance and fluorescence based molecular imaging technologies.- Studying molecular and cellular processes in the intact organism.- Disease phenotyping: structural and functional readouts.- Evaluation of drug candidates: Efficacy readouts during lead optimization.- Risk identification and management: MRI as a research tool in toxicology studies of new chemical entities.- Pharmacokinetic studies with PET.- Imaging bio-markers predictive of disease/therapy outcome: ischemic stroke and drug development.- Clinical drug evaluation using imaging readouts: regulatory perspectives.
The drug discovery process.- Imaging modalities: principles and information content.- Magnetic resonance and fluorescence based molecular imaging technologies.- Studying molecular and cellular processes in the intact organism.- Disease phenotyping: structural and functional readouts.- Evaluation of drug candidates: Efficacy readouts during lead optimization.- Risk identification and management: MRI as a research tool in toxicology studies of new chemical entities.- Pharmacokinetic studies with PET.- Imaging bio-markers predictive of disease/therapy outcome: ischemic stroke and drug development.- Clinical drug evaluation using imaging readouts: regulatory perspectives.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497